Mobile

A Phase 3 Randomized, Double-Blind, Placebo-controlled study of Idelalisib (GS-1101) in Combination with Rituximab for Previously Treated CLL

Update Il y a 4 ans
Reference: EUCTR2011-005180-24

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To evaluate the effect of the addition of idelalisib (formerly GS-1101) to rituximab on progression-free survival (PFS) in subjects with previously treated chronic lymphocytic leukemia (CLL).

Inclusion criteria

  • Chronic lymphocytic leukemia (CLL)

Links